Catalog No.
DHJ85301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-lambda
Clonality
Monoclonal
Target
BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor
Concentration
1.73 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9Y275
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
LymphoStat-B, hBlySmAb-1.1, CAS: 356547-88-1
Clone ID
Belimumab
Belimumab: A Review in Systemic Lupus Erythematosus, PMID: 29396833
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis, PMID: 32937045
Belimumab as Add-on Therapy in Lupus Nephritis, PMID: 32937052
Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents, PMID: 32695790
Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review, PMID: 28147262
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, PMID: 22127708
Efficacy of belimumab in Primary Sjögren's syndrome: A systematic review, PMID: 32451263
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, PMID: 21296403
Belimumab in lupus nephritis, PMID: 33024302
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial, PMID: 32699034
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis, PMID: 32755035
Belimumab, PMID: 31644070
The safety of belimumab for the treatment of systemic lupus erythematosus, PMID: 31657965
Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab, PMID: 32612353
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study, PMID: 28118533
Belimumab, PMID: 29999643
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol, PMID: 30898822
Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review, PMID: 29514612
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea, PMID: 29295825
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial, PMID: 31848169
Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study, PMID: 30666823
Subcutaneous belimumab in the treatment of systemic lupus erythematosus, PMID: 30105936
B cell alterations during BAFF inhibition with belimumab in SLE, PMID: 30593436
Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE, PMID: 23263865
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus, PMID: 30771238
Adding belimumab improves lupus nephritis, PMID: 32994586
The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus, PMID: 29636274
Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension, PMID: 31302695
Efficacy of a sequential treatment by belimumab in monogenic systemic lupus erythematosus, PMID: 32910770
Belimumab, PMID: 21532557
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response, PMID: 22337213
Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States, PMID: 29409143
Belimumab in kidney transplantation, PMID: 30837144
Belimumab in kidney transplantation, PMID: 30837143
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting, PMID: 32275125
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus, PMID: 22275291
Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis, PMID: 30610066
Systemic lupus erythematosus, PMID: 27306639
Update οn the diagnosis and management of systemic lupus erythematosus, PMID: 33051219
Belimumab: review of use in systemic lupus erythematosus, PMID: 22464040
Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction, PMID: 30538431
Belimumab in the management of systemic lupus erythematosus - an update, PMID: 28460578
Belimumab Treatment for Adults with Systemic Lupus Erythematosus: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet], PMID: 30379511
Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus, PMID: 33245847
Pharmacoeconomic Review Report: Belimumab (Benlysta): (GlaxoSmithKline Inc.) [Internet], PMID: 33237683
Belimumab: in systemic lupus erythematosus, PMID: 22141386
Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies, PMID: 30666173
Systematic review of safety and efficacy of belimumab in treating immune-mediated disorders, PMID: 33368349
Successful treatment of systemic lupus erythematosus pleuropericarditis with belimumab, PMID: 31364982
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials, PMID: 22550315
For research use only. Not for human or drug use.
